What did @daybydaydesiree actually say?
The creator is promoting a telehealth platform called Fridays, where she has an affiliate code. She claims GLP-1 medications cost $249 per month, a dual GLP-1/GIP option runs $359, and her code saves $100. She also pitches a "microdosing" tier at $199 for people "under 25% body fat" who don't qualify for standard GLP-1 prescribing. She frames flat-rate pricing as a consumer protection feature, warning viewers to "beware" of companies that hide costs. The pitch is clear: quiz in bio, talk to a doctor after, and use her code. This is not a medical education video. It is an affiliate marketing video with some accurate information mixed in.
The #tiktokpartner and #joinfridays hashtags confirm this is paid promotional content, which the creator does not verbally disclose during the clip itself.
Does the science back this up?
GLP-1 receptor agonists are legitimate, FDA-studied drugs. The underlying medication class is real and well-documented. But none of that science applies cleanly to what compounded telehealth platforms are actually dispensing.
Semaglutide and tirzepatide, the active ingredients in Ozempic, Wegovy, Mounjaro, and Zepbound, have robust clinical trial data. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide produced up to 22.5% body weight reduction over 72 weeks in adults with obesity. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide at 2.4mg produced roughly 14.9% weight loss versus 2.4% for placebo. These are brand-name, FDA-approved drugs at studied doses.
Compounded semaglutide and tirzepatide are different products. The FDA has repeatedly warned that compounded versions are not FDA-approved and have not been evaluated for safety, efficacy, or quality in the same way. In 2024, the FDA removed semaglutide from the drug shortage list and moved to restrict compounding. The science behind the drug class is strong. The science behind the specific products being sold here is not the same thing.
What did they get wrong (or right)?
Credit where it's due: the creator is right that pricing transparency matters. Many compounded GLP-1 telehealth platforms bury dose-escalation costs, so flat-rate pricing is a genuinely consumer-friendly model if it holds in practice. Recommending viewers confirm pricing upfront is reasonable advice.
The "25% body fat" threshold for microdosing qualification is where things go sideways. There is no peer-reviewed clinical standard establishing 25% body fat as a GLP-1 eligibility cutoff. FDA-approved GLP-1 indications use BMI thresholds (BMI 30 or greater, or BMI 27 or greater with a weight-related comorbidity), not body fat percentage. The creator is describing a telehealth platform's proprietary eligibility criteria, not a medical standard, and presenting it as if it were clinical fact.
"Microdosing" GLP-1s also has no standardized clinical definition. It is a marketing term. Sub-therapeutic dosing may reduce side effects but there is no published randomized trial establishing what dose constitutes a "microdose" or what outcomes users should expect from it.
What should you actually know?
If you're considering a compounded GLP-1 from a telehealth platform, there are several things the creator's video does not tell you. First, compounded semaglutide and tirzepatide are not FDA-approved drugs. They are made by 503A or 503B compounding pharmacies, and their quality, sterility, and dosing accuracy vary. The FDA has issued multiple safety communications on this.
Second, "talking to a doctor" after completing a quiz is not the same as a thorough clinical evaluation. A legitimate prescriber should review your full medical history, current medications, and contraindications, including personal or family history of medullary thyroid carcinoma, which is a boxed warning on all GLP-1 labels.
Third, the affiliate relationship here means the creator has a direct financial incentive to get you to sign up. That does not make the platform bad, but it does mean you should verify claims independently before spending $249 or more per month.
- Ask any telehealth platform specifically which compounding pharmacy they use and whether it is FDA-registered.
- Confirm the active ingredient and formulation, since some compounded products have used semaglutide salt forms the FDA has flagged as potentially problematic.
- Check whether the prescriber is licensed in your state.
- Understand that pricing may change and get any flat-rate guarantees in writing.